Accelerating Medicines Partnership Completes Key Phase
September 24, 2019 The Accelerating Medicines Partnership (AMP) RA/Lupus Program, a joint effort involving the National Institutes of Health (NIH), the Foundation for NIH, pharmaceutical companies, and non-profit organizations such as the Lupus Research Alliance, has reached a milestone, finishing an important phase of its studies. Researchers with the AMP RA/Lupus Program have published a […]
Investigational CAR T Cell Gets Fast Tracked by U.S. FDA
May 1, 2023 The LRA and our clinical arm Lupus Therapeutics are pleased to share good news from Cabaletta Bio, Inc. that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for CABA-201, a CAR T cell investigational therapy in development to treat systemic lupus erythematosus and lupus nephritis – a common […]
Results of Two Voclosporin Trials Presented at Key Medical Meeting
October 22, 2020 Aurinia Pharmaceuticals announced that data taken from a combined analysis of two trials, AURA-LV and AURORA underscored the potential for voclosporin to offer a tool to treat lupus nephritis. Results from 534 patients from both trials was presented at the American Society of Nephrology Kidney Week 2020 meeting by Dr. Brad Rovin, […]
New TIL Grantees Offer Novel Approaches
Sept. 7, 2017. Grantees of our Target Identification in Lupus (TIL) program are remarkable scientific investigators whose ingenuity and determination are bringing new insights to lupus research. The Lupus Research Alliance congratulates each of these brilliant researchers in their quest to expand our understanding of lupus and ways to defeat it: Kerstin Nundel, PhD University […]
Data Shows Voclosporin Preserves Kidney Function for Three Years
July 19,2023 The LRA is pleased to share news announced by Aurinia Pharmaceuticals of published results showing that the lupus treatment, voclosporin (Lupkynis) preserved kidney function up to three years among lupus nephritis. These results of the Phase 3, double-blind, placebo-controlled AURORA 2 extension study were published in the official peer-reviewed professional journal of the […]
Aurinia Announces Voclosporin Meets 48-Week Remission Endpoints
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (“Aurinia” or the “Company”), a clinical stage biopharmaceutical company focused on the global immunology market, today announced top-line results from its Phase IIb AURA-LV (AURA) study in lupus nephritis (LN). At 48 weeks, the trial met the complete and partial remission (“CR”/ “PR”) endpoints, demonstrating statistically significantly greater CR […]
LIC Accomplishments
As of December 2019 Determinants of ANA Expression in Patients with Lupus PI: David Pisetsky (Duke University) Co-PIs: Megan Clowse (Duke University), Peter Lipsky (AMPEL BioSolutions LLC), Dr. Brad Rovin, Ohio State University Project Status: Completed in 2018 The goal of this study was to assess the expression of antinuclear antibodies (ANA) in SLE, focusing […]
Advancing Research Exponentially
August 14, 2018 Advancing Research Exponentially An Update on AMP by Jill Buyon, MD Lupus nephritis (LN), one of the dreaded complications of lupus, causes patients to suffer, sometimes for decades, with no new treatment in sight. But now is the time to leverage technology for major advances, which is exactly what the Accelerating Medicines […]
Living in a Disadvantaged Neighborhood Lowers Follow-up Care
March 4, 2020 A new study showed that living in a disadvantaged neighborhood predicts poor retention (follow-up) care for people with lupus. Retention was defined specifically has having two out-patient doctor visits or lab tests such as measuring complement levels. Researchers looked at the records of 397 patients with lupus in terms of age, sex, […]
KZR-616 Shows Promise According to Results Reported at EULAR
Kezar Life Sciences announced positive results from the MISSION Phase 1 study testing the investigational KZR-616 as a treatment for lupus. The presentation was at the European League Against Rheumatism (EULAR) 2019 annual meeting. The primary goal of the study was to assess if KZR-616 is safe and well tolerated. The study also looked at […]